SME
Description
We are an innovative R&D company with two missions:
develop novel miRNA therapeutics (oligonucleotide drugs) for cardiovascular, oncology, musculoskeletal, and women’s health diseases supported by AI-driven drug discovery tools
provide services globally focusing on in vitro and in vivo models of cardiovascular, metabolic, renal, inflammation, oncology, musculoskeletal, and women’s health diseases from cells to large animals. Unique service: small and large animal multicenter studies for myocardial infarction and heart failure.
We are looking for:
investors and co-development partners: development of miRNA therapies for cardiovascular, oncology, musculoskeletal, and women’s health diseases by proprietary AI-driven drug discovery tools. Pharmahungary Group is one of the pioneers in the development of microRNA (miRNA) therapies. Our first patent ‘Compounds for the treatment of ischemic injuries’ was granted in the USA in 2016 protecting over 20 million cytoprotective and cardioprotective oligonucleotide sequences. Several follow-up patents are in the pipeline. Pharmahungary Group also developed several novel AI-driven drug discovery software tools for the prediction of mRNA targets of miRNAs (www.miRNAtarget.com) as well as a software with the capability to identify specific miRNA sequences to target specific genes or pathways of any disease.
customers for our preclinical services: in vitro and in vivo models of cardiovascular, metabolic, renal, inflammation, oncology, musculoskeletal, and women’s health diseases from cells to large animals
Since 2001 Pharmahungary Group has been offering global services focusing on in vivo and in vitro models of cardiovascular, metabolic, renal, inflammation, oncology, musculoskeletal, and women’s health diseases. Pharmahungary Groups has demonstrated capabilities to accomplish preclinical studies with excellent records of client satisfaction regarding quality, timelines, and budgets in over 350 development projects including drugs and medical devices. Our innovative R&D services include in vitro and in vivo efficacy models with cardiac cells, small and large animal models of cardiovascular, metabolic, renal (myocardial infarction, heart failure, arrhythmias, diabetes, insulin resistance, hyperlipidemia, atherosclerosis, uremia, obesity, etc.), inflammation, oncology (triple-negative breast cancer, small-cell lung cancer), musculoskeletal (sarcopenia), and women’s health diseases. Custom-designed and cardiovascular co-morbidity models such as myocardial infarction with risk factors and co-morbidities such as hyperlipidemia and diabetes are also available. We are also providing a unique service, i.e. small and large animal multicenter studies for myocardial infarction and heart failure performed in an international consortium in order to generate more robust data for your drug candidates. Our novel cardiac safety testing platform hiddentox™ involving combined experimental models of cardiac diseases (especially myocardial ischemia/reperfusion and ischemic conditioning) in the presence and absence of major cardiovascular comorbidities and/or cotreatments is also available.
